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Bacteriophages, viruses that infect bacteria, have numerous applications in the medical, agricultural, and
research fields, especially as an alternative to antibiotics in the age of antibiotic resistance. Phages are able
to lyse, or break apart, bacterial cells with fewer side effects, more specificity, and less likelihood of resistance
than antibiotics. The acceptance of phages in medicine and agriculture around the world today is not
universal, and the United States Food and Drug Administration (FDA) has been slow to recognize phage
therapy as a legitimate treatment. However, the successful use of phages in the past, as well as promising
trial results in fields ranging from chronic disease treatment to food preservation, present opportunities for
consideration of phage-based applications in the future. The goal of this paper is to provide an overview of
the history, uses, and regulation of phage therapy.
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Introduction

If you were to walk out into your backyard today,
you probably wouldn’t notice the thousands of tiny
microorganisms living there right underneath your feet.
Many of these microorganisms would be bacteria, but
at least ten times as many would be their viral predators
(Hattful, 2008). These bacteria-infecting viruses, called
bacteriophages or “bacterium-eaters,” were discovered in
1910 by Felix d’Herelle, a French-Canadian microbiologist
(Golkar, Bagasra, & Pace, 2014). One example of a
bacteriophage is shown in Figure 1. They can be found
almost anywhere on Earth and are a topic of increasing
study, especially due to the dramatic rise of antibiotic
resistance. Bacteriophage research is conducted worldwide
in an effort to combat this resistance and address a variety
of health issues, ranging from chronic diseases to safety in
the food industry.

communication between Eastern Europe and the Western
world during World War II and the counterintuitive nature
of using viruses to treat diseases (Summers, 2012). In
addition, the difficulty in regulating a virus as a therapeutic
agent is still a major barrier.
During World War II, the Allied and Axis powers differed
in regard to method of treatment for bacterial infections.
While German scientists studied phages, the Allies were
heavily dependent on antimicrobial drugs like penicillin
and amoxicillin (Summers, 2012). The efficacy and speed
of these pharmaceuticals were a major breakthrough in
the medical industry, surpassing the still-developing phage
therapy. Antimicrobial drugs were produced in great
quantities, rendering phage therapy virtually obsolete.
Recently, the emergence of bacterial resistance to antibiotics
has caused researchers to seek alternative methods of
treatment (Yosef, Kiro, Molshanski-Mor, Edgar, & Qimron,
2014).
Although ignored for several decades in the West, the
decline of phage therapy was neither uniform nor complete,
as evidenced by its continued use in the Republic of Georgia
by the Tbilisi Institute (Kutateladze & Adamia, 2008). No
substantial research or well-documented practice of phage
therapy arose for the next 40 years; however, in the last
few decades phage therapy research has reemerged in the
Western world to combat the urgent problem of antibiotic
resistance.

Current Uses and Future Applications of
Phages

While many phage treatments are not yet supported by
the United States’ Food and Drug Administration (FDA),
research has shown phages to be beneficial in areas like
food preservation, agriculture, livestock health, and the
treatment of human infections. Several uses that will
be discussed include overcoming antibiotic resistance,
sterilizing medical equipment, and treating agricultural
products.

Figure 1. An electron micrograph image of a siphovirus
isolated by Isabel Jimenez-Bush from a soil sample in a JMU
Viral Discovery class. Note the icosahedral head along with
the long flexible tail.

History of Phage Therapy

The use of bacteriophages to treat pathological bacterial
infections, called phage therapy, began in France in 1919.
By the 1930s, phage therapy was in use in Europe and the
United States (Highfield, 2014). After the introduction
of antibiotics, however, phage therapy became virtually
obsolete everywhere except Eastern Europe and the
Soviet Union. The decline in phage therapy was the result
of multiple factors, including the cessation of research

A promising technique for overcoming antibiotic resistance
involves using specific proteins from phages that lyse
bacteria, and can be isolated and used to treat bacterial
infections. Phage therapy significantly increases the
ability to combat antibiotic resistance in bacteria such as
Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella
pneumoniae, and Escherichia coli with 90% efficiency (Pirisi,
2000). These bacteria are known to cause a variety of health
problems like staph infections, pneumonia, bronchitis,
meningitis, and gastroenteritis, respectively. Additionally,
phages are effective against ten of the most antibioticresistant strains of E. coli (Rahmani, Zarrini, Sheikhzadeh,
& Aghamohammadzadeh, 2014). Table 1 shows several
comparisons between bacteriophages and antibiotics and
offers a condensed view of phage therapy viability. The
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Table 1. Comparing and Contrasting Bacteriophages and Antibiotics

Side Effects

Targeting Ability

Site
Specificity

Resistance

Bacteriophages No serious

known side
effects

Infect targeted
pathogenic
bacteria

Congregate at
infection site

Rarely encounter
phage-resistant
bacteria which
are typically
susceptible to other
phages

Antibiotics

Can cause side
effects such
as allergies,
intestinal
disorders, and
secondary
infections

Target both
pathogenic
microorganisms
and normal
microflora, which
affects microbial
balance in patients

Do not
concentrate at
the infection
site and are
eliminated
from the body
over time

Antibioticresistant bacteria
are common and
develop from nonselected bacteria
during antibiotic
treatment

Treatment
Development
Can easily select
specific phages
to develop new
treatments
quickly; new
phage treatments
are easy to
develop due to
high specificity of
phages
New antibiotics
are developed
slowly

Note. Chart adapted from “Bacteriophage Therapy,” by A. Sulakvelidze, Z. Alavidze, and J. G. Morris, 2001, Antimicrobial Agents
and Chemotherapy, 45(3), 649–659.

use of phages as antibacterial agents in the past century in
other places than the United States has had a lasting impact
on the treatment of bacterial infections (Abedon, Kuhl,
Blasdel, & Kutter, 2011).
Regulating Applications of Phage Therapy
The policy decisions regarding characterization of phages
as medicinal products are controversial due to the varying
definitions of bacteriophages and efficacy of phage therapy.
In many countries, phage therapy is placed into one or
more of three categories: a general medicinal product,
a biological medicinal product (such as a vaccine), or an
advanced medicinal product (such as gene therapy). In
Europe, phage therapy is already implemented and is
considered a biological and medicinal product suitable
for human use (Verbeken et al., 2014). The European
Regulatory Framework dictates that phage therapy should
be delivered through a mixture of bacteria-specific phages
also known as “phage cocktails.” For non-life-threatening
infections, these cocktails are sold over the counter. Phage
cocktails that target potentially life-threatening bacterial
infections, however, are only administered in a hospital
setting (Verbeken et al., 2014).
Phage Cocktail Therapy has yet to be fully supported by
the FDA for direct treatment of human disease because
each phage must be approved individually (Keen, 2012).
An example of the FDA’s hesitation toward this type of
therapy is the production of Staphylococcal Phage Lysate
(SPL) in 1959. SPL can be used to treat wounds infected
with Staphylococcus aureus and after safety trials were
conducted, SPL was licensed for administration in human
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treatment. However, the production of SPL for human
treatment was suspended in the 1990s due to regulatory
pressure from government agencies. Currently, SPL is
approved and utilized only for veterinary applications
(Golkar et al., 2014).
In regard to the food industry, in 2006 the FDA approved
phage food additives to combat contamination, particularly
for anti-Listeria treatment (“Food Safety,” 2015). Phages
can be used to treat Listeria in ready-to-eat meat, and
bacterial damage of tomatoes and peppers, and treatments
are recognized as compatible with organic food production.
Additionally, the FDA has approved phage use in treatment
of bacterial pathogens such as E. coli, Salmonella, and
Campylobacter (Golkar et al., 2014).
Phage Therapy and Campylobacter jejuni.
The use of phages in the food industry includes the
treatment of the Campylobacter jejuni bacterium. The
Campylobacter jejuni bacterium is the most common cause
of gastroenteritis in humans. Commonly found in the feces
and intestinal tracts of poultry, the C. jejuni bacterium
causes contamination of poultry meat. One method of
preventing infection involves dosing live poultry with
bacteriophage cocktails to lessen the amounts of C. jejuni
in their intestinal tracts (Hammerl et al., 2014).
Hammerl et al. (2014), studied the effects of the introduction
of the Myoviridae bacteriophage family on the C. jejuni
bacterium found in broiler chickens. In this study, some
chickens were treated with single phages and others with
groups of phages (Hammerl et al., 2014). The phages were

categorized into three groups based on genome size and
morphology. Phages in group II were able to infect more
strains of bacteria than group III, though some of the
phages in group III had a higher lytic activity, meaning they
were more effective at killing the bacteria of the strains that
they were able to infect. After comparing the ability of these
phage groups to reduce C. jejuni numbers, the researchers
found that the chickens treated with a combination of
phages from groups II and III had the greatest reduction
of C. jejuni in their intestinal tracts (Hammerl et al., 2014).
The results of this study could positively impact the future
of food safety.
Phage Therapy and Pseudomonas aeruginosa.
Pseudomonas aeruginosa is an opportunistic, multidrugresistant bacterium commonly found among the human
microbial flora of the skin. However, if this seemingly
harmless bacterium is introduced into the bloodstream,
it can cause serious complications, including sepsis, an
often fatal bacterial infection of the blood (Vieira et al.,
2012). Vieira et al. (2012) demonstrated in their study
that immediately after phages were
applied to infected human skin
the amount of resistant bacteria
significantly decreased from a
control of 106 CFU (colony forming
units) per square centimeter to
102 CFU per square centimeter.
This nearly ten billion CFU per
square centimeter drop supports the effectiveness of phage
therapy. In addition, the experiment exhibited that only
one application of phages was necessary as subsequent
applications did not lower the bacterial concentration. This
proves promising for treating multidrug-resistant bacterial
infections using phage therapy (Vieira et al., 2012).

of disease-causing phages could allow for development of
new and effective treatments.
Phage Application in Cleaning Surfaces
Another environment prone to resistant bacteria is hospital
equipment. Bacterial colonies growing on the surfaces
of hospital equipment often come into contact with
antibacterial cleaning supplies. This common interaction
allows the bacteria to develop resistance to these cleaners.
Research is being conducted to devise a technique to
clean hospital surfaces while treating resistant bacteria
using bacteriophages (Viertel, Ritter, & Horz, 2014). These
cleaners prove less of a hurdle for regulation due to the fact
that they would not be used directly on humans.
Susceptibility in Antibiotic-Resistant Bacteria
Another technique to combat antibiotic resistance is to use
phages that insert their genome into the host bacterium to
transfer susceptibility genes back into the bacterial genome
(Viertel et al., 2014). This allows bacteria that were once
antibiotic resistant to regain susceptibility to antibiotics.
This occurs because the genes that
are transferred into the bacterium
increase the permeability of its cell
membrane and allow medications
to pass through it more freely.
Therefore, doctors will be able to
use antibiotics that they are familiar
with, an approach that is more
likely to be accepted by the FDA (Viertel et al., 2014).

The identification of
disease-causing phages could
allow for development of
new and effective treatments.

Potential Use of Phages in Treatment of Crohn’s Disease
Another use of phage therapy in medical research can be
seen through the treatment of Crohn’s disease (CD). CD is
commonly called regional enteritis, or inflammatory bowel
disease, and its cause is unknown. Josef Wagner, researcher
at Murdoch Children’s Research Institute, has investigated
the differences in the bacteriophages present within the
gut and small intestine of pediatric patients that have CD
(Wagner et al., 2013). The researchers analyzed the genome
of the phages to determine if these phages were unique
to the intestines. Ultimately, they found that CD patients
exhibited a higher amount of unique bacteriophages
compared to their control counterparts. Overall, the large
abundance of phage composition within CD ileum tissue
and CD gut wash samples suggests a role of phages in CD
development. Researchers assumed that the increase in
the amount of phages indicated that the bacterial count
was higher. Therefore, the presence of specific phages may
coincide with specific bacterial counterparts (Wagner et al.,
2013). Because phages are host-specific, the identification

Endolysins
Endolysins are phage-produced enzymes that rupture a
bacterial host cell. These endolysins are specific proteins
with known structures that can be defined and therefore
regulated. The controversies surrounding use of whole
phages or mixtures of phages, including their chemical
and biological classification, may ultimately inhibit the
approval of phage therapy in the U.S. However, endolysins
may provide a solution. As endolysins are static chemicals
similar to antibiotics, they may prove more successful in
regulation and approval by the FDA.
In addition, endolysins are only required in small doses
(Ghannad & Mohammadi, 2012). Researchers at Seoul
National University in South Korea studied the use of
a phage called PCB1 against Bacillus cereus, a bacterium
known to cause food poisoning in humans. PCB1 itself was
only able to successfully infect 1 out of 22 B. cereus strains;
however, the purified endolysins produced by the phage
were able to successfully lyse all strains of Bacillus bacteria
(Kong & Ryu, 2015). The lytic activity of the endolysin
suggests that these chemicals not only appear to be more
favorable due to their static nature, but also may have
broader and more successful applications against bacteria
than phages themselves
JAMES MADISON UNDERGRADUATE RESEARCH JOURNAL 39

Combination Therapy
The most successful phage therapy is the combined usage
of bacteriophages and antibiotics. By using this technique,
treatment has shown a promising increase in the reduction
of bacterial infection and reducing the amount of bacteria
evolving to develop antibiotic resistance. In the future,
using both bacteriophages and antibiotics to fight infections
may appease drug companies that seek the opportunity
to continue producing their own medications, while
increasing the effectiveness of phage therapy treatment
(Viertel et al., 2014).

Conclusion

Phage therapy presents numerous advantages and options
for medical research and scientific application. It is not
currently in use in the United States due to a lack of
regulatory ability and a large-scale control study, as well as
the controversies surrounding the use of phages. New routes
of regulation and classification will have to be established
for phages to enter mainstream use in the U.S. Phages
are being studied with broader host ranges, and being
tested on their ability to kill pathogenic bacteria without
harming the patients or destroying the body’s natural
flora. Other areas of phage research include sterilization
techniques for hospital equipment, endolysin usage that
may surpass phage usage alone, and combination of phage
and antibiotic therapies that could potentially result in
approval for future use of phages. Phage research has
also shown promising results in reintroducing antibiotic
susceptibility into antibiotic resistant bacteria, which has
become an increasingly prevalent issue in the modern
medical world. In addition to combatting antibiotic
resistance, phage therapy could eventually be used as a
more effective alternative for bacterial infections. For these
reasons, phages are a promising medical and industrial tool
worldwide in the future.
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